Atopic dermatitis, psoriasis, vitiligo
Conditions
Interventions
Trial Group:Use of intelligent platform medical companion for continuous follow-up, including but not limited to medical education, medication guidance, treatment reminders, and nutritional support, a
Control Group:No use of intelligent management platform
routine follow-up visits with feedback on medication adherence and adverse reactions
Sponsors
Shenzhen People’s Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Be 18 years of age or older; 2. Patients who have been clinically diagnosed with atopic dermatitis, psoriasis, vitiligo, and plan to receive treatment or are being treated; 3. The patient is able to understand the purpose of the trial, voluntarily participate in and sign the informed consent form, and is willing to complete the follow-up according to the requirements of the protocol; 4. Be aware and be able to answer questions correctly; 5. Be proficient in using a smartphone or complete software download and project transfer feedback with the help of relatives.
Exclusion criteria
Exclusion criteria: 1. Have a serious underlying medical condition or poor physical condition; 2. Pregnant or lactating women; 3. Unable to receive treatment due to the patient's refusal or organ function, complications, etc.; 4. Participate in other clinical trials at the same time; 5. Lack of information such as past medical history, examination and examination, and treatment status; 6. Patient refuses to provide data or refuses to participate in the study; 7. Other situations judged by the investigator to be inappropriate to participate.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Dermatology Life Quality Index (DLQI); | — |
Secondary
| Measure | Time frame |
|---|---|
| Dermatology Life Quality Index (DLQI);Dermatology Life Quality Index (DLQI);Dermatology Life Quality Index (DLQI);Psoriasis Area and Severity Index (PASI);Psoriasis Area and Severity Index (PASI);Psoriasis Area and Severity Index (PASI);Eczema Area and Severity Index (EASI);Eczema Area and Severity Index (EASI);Eczema Area and Severity Index (EASI);Total Vitiligo Area Scoring Index (T-VASI);Total Vitiligo Area Scoring Index (T-VASI);Total Vitiligo Area Scoring Index (T-VASI);Facial Vitiligo Area Scoring Index (F-VASI);Facial Vitiligo Area Scoring Index (F-VASI);Facial Vitiligo Area Scoring Index (F-VASI); | — |
Countries
China
Contacts
Public ContactZhang Jianglin
Shenzhen People's Hospital (First Affiliated Hospital of Southern University of Science and Technology; Second Clinical Medical College of Jinan University)
Outcome results
None listed